Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.

Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K

Open source

DOI: 10.1093/oncolo/oyab025
Published: 2022 Apr 5
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyab025,
  title = {Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.},
  author = {Lipsyc-Sharf M and Ou FS and Yurgelun MB and Rubinson DA and Schrag D and Dakhil SR and Stella PJ and Weckstein DJ and Wender DB and Faggen M and Zemla TJ and Heying EN and Schuetz SR and Noble S and Meyerhardt JA and Bekaii-Saab T and Fuchs CS and Ng K},
  year = {2022},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyab025},
  url = {https://doi.org/10.1093/oncolo/oyab025}
}

RIS

TY  - JOUR
TI  - Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
AU  - Lipsyc-Sharf M
AU  - Ou FS
AU  - Yurgelun MB
AU  - Rubinson DA
AU  - Schrag D
AU  - Dakhil SR
AU  - Stella PJ
AU  - Weckstein DJ
AU  - Wender DB
AU  - Faggen M
AU  - Zemla TJ
AU  - Heying EN
AU  - Schuetz SR
AU  - Noble S
AU  - Meyerhardt JA
AU  - Bekaii-Saab T
AU  - Fuchs CS
AU  - Ng K
PY  - 2022
JO  - The oncologist
DO  - 10.1093/oncolo/oyab025
UR  - https://doi.org/10.1093/oncolo/oyab025
ER  -

APA

M, L., FS, O., MB, Y., DA, R., D, S., SR, D., PJ, S., DJ, W., DB, W., M, F., TJ, Z., EN, H., SR, S., S, N., JA, M., T, B., CS, F., & K, N. (2022). Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.. The oncologist. https://doi.org/10.1093/oncolo/oyab025

Source records

pubmed · retrieved 2026-09-26T13:43:06.360Z